Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

12_09 Cybersecurity and Data Privacy

Cybersecurity & Data Privacy for Life Sciences Companies

Cybersecurity & Data Privacy for Life Sciences Companies

Summary

Speakers

Matt Wetzel

Related Content

How the Trump Administration Could Reshape Regulation in the Life Sciences Sector

Massachusetts Passes Comprehensive Revisions to Healthcare Transaction Notification Law with Significant Implications for Private Equity Healthcare Investments

DEA Announces a Third Extension of COVID-19 Telehealth Flexibilities for Prescription of Controlled Medications

Business Groups File Lawsuit Challenging HSR Rule Changes

2025 HSR Thresholds Announced: $126.4 million

HHS Proposes Major Revisions to HIPAA Security Rule

Changes Expected as Trump Administration Continues to Take Shape

Health Headlines

Goodwin Named a Law360 Practice Group of the Year for Capital Markets

Goodwin CLE Week 2025

Goodwin Ranks Number One for Global M&A for the Fifth Consecutive Year

Hidden Gold – Section 1202 and the PE Playbook

AlloVir and Kalaris Therapeutics to Merge

Retina Consultants of America To Be Acquired By Cencora For Up To $5.1 Billion

Goodwin Becomes First Tenant at 3025 JFK, Settles in Ahead of Lateral Hiring Season (Philadelphia Business Journal)

Goodwin Advises CareBridge in Acquisition by Elevance Health

Healthcare

Medtech

Healthcare Disputes & Investigations